Phase I randomized double-blind parallel-group study: pharmacokinetics, safety, and immunogenicity of pertuzumab biosimilar SYSA1901 in healthy Chinese males
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04966-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Yucai Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Pertuzumab, administered as an injection, is an antagonist of human epidermal growth factor receptor 2 (HER2). This study sought to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity between pertuzumab biosimilar SYSA1901 injection and the reference product (Perjeta®) in healthy males. In this single-center, randomized, double-blind, parallel-group, single-dose trial, 88 male subjects were enrolled and randomized into two groups, each receiving a single 420 mg (14 mL) intravenous infusion of SYSA1901 or pertuzumab (Perjeta®), respectively. Primary endpoint: serum concentration-time curve area from 0 to infinity (AUC0-∞). Secondary endpoints: AUC from 0 to last quantifiable concentration (AUC0-t), maximum serum concentration (Cmax), safety, and immunogenicity. For the key PK parameters of SYSA1901 relative to Perjeta®, the geometric mean ratios (GMRs) were as follows: AUC0-∞ at 90.23% (95% CI: 84.41%-96.45%), AUC0-t at 90.25% (95% CI: 84.48%-96.42%), and Cmax at 94.69% (95% CI: 90.46%-99.12%). All GMRs fell within the pre-specified bioequivalence range of 80.00%-125.00%. SYSA1901 and Perjeta® demonstrated comparable PK profiles, with no clinically significant differences in safety or immunogenicity. In this study, SYSA1901 injection and Perjeta® showed similar PK profiles, safety, and immunogenicity. These findings support further clinical investigations of the investigational drug in breast cancer. TRIAL REGISTRATION: This trial was registered on the Chinese Clinical Trial Registry (URL: http://www.chinadrugtrials.org.cn/index.html ) under Test Protocol No. SYSA1901-001 and Registration No. CTR20212874. Registration date: 3 September 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
- School of Pharmaceutical Sciences, Anhui Medical University, Hefei, 230032, China.
- CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, 050000, Hebei Province, China.
- Anhui Provincial Institute of Translational Medicine, Hefei, 230022, China.
- Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China. zhourenpeng@ahmu.edu.cn.
- Anhui Provincial Institute of Translational Medicine, Hefei, 230022, China. zhourenpeng@ahmu.edu.cn.
Zitieren
APA
Xu, Y., Zhang, X., Zhang, H., Yang, J., Zhang, Q., Qin, H., Zhang, Q., Zhang, W., Zhou, R., Hu, W., & Li, C. (2026). Phase I randomized double-blind parallel-group study: pharmacokinetics, safety, and immunogenicity of pertuzumab biosimilar SYSA1901 in healthy Chinese males. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04966-3
Vancouver
Xu Y, Zhang X, Zhang H, Yang J, Zhang Q, Qin H, et al. Phase I randomized double-blind parallel-group study: pharmacokinetics, safety, and immunogenicity of pertuzumab biosimilar SYSA1901 in healthy Chinese males. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04966-3
BibTeX
@article{Xu2026,
author = {Xu, Yucai and Zhang, Xueyuan and Zhang, Hailin and Yang, Jingjing and Zhang, Qian and Qin, Huiling and Zhang, Qin and Zhang, Wei and Zhou, Renpeng and Hu, Wei and Li, Chunlei},
title = {Phase I randomized double-blind parallel-group study: pharmacokinetics, safety, and immunogenicity of pertuzumab biosimilar SYSA1901 in healthy Chinese males},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04966-3}
}
EUVIMED